JP2020503891A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020503891A5 JP2020503891A5 JP2019551736A JP2019551736A JP2020503891A5 JP 2020503891 A5 JP2020503891 A5 JP 2020503891A5 JP 2019551736 A JP2019551736 A JP 2019551736A JP 2019551736 A JP2019551736 A JP 2019551736A JP 2020503891 A5 JP2020503891 A5 JP 2020503891A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cells
- cell
- car
- cell according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023017202A JP2023052980A (ja) | 2016-12-09 | 2023-02-07 | 操作されたナチュラルキラー細胞およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662432302P | 2016-12-09 | 2016-12-09 | |
| US62/432,302 | 2016-12-09 | ||
| PCT/EP2017/082292 WO2018104562A1 (en) | 2016-12-09 | 2017-12-11 | Engineered natural killer cells and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023017202A Division JP2023052980A (ja) | 2016-12-09 | 2023-02-07 | 操作されたナチュラルキラー細胞およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020503891A JP2020503891A (ja) | 2020-02-06 |
| JP2020503891A5 true JP2020503891A5 (enExample) | 2021-01-21 |
| JP7228900B2 JP7228900B2 (ja) | 2023-02-27 |
Family
ID=60937693
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019551736A Active JP7228900B2 (ja) | 2016-12-09 | 2017-12-11 | 操作されたナチュラルキラー細胞およびその使用 |
| JP2023017202A Pending JP2023052980A (ja) | 2016-12-09 | 2023-02-07 | 操作されたナチュラルキラー細胞およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023017202A Pending JP2023052980A (ja) | 2016-12-09 | 2023-02-07 | 操作されたナチュラルキラー細胞およびその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10799536B2 (enExample) |
| EP (4) | EP3895712B1 (enExample) |
| JP (2) | JP7228900B2 (enExample) |
| KR (1) | KR20190114966A (enExample) |
| CN (2) | CN117305250A (enExample) |
| AU (1) | AU2017371517B2 (enExample) |
| BR (1) | BR112019011450A2 (enExample) |
| CA (1) | CA3045386A1 (enExample) |
| DK (2) | DK3454871T3 (enExample) |
| ES (3) | ES2746856T3 (enExample) |
| MX (1) | MX2019006598A (enExample) |
| WO (1) | WO2018104562A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10906951B2 (en) * | 2015-07-29 | 2021-02-02 | Onk Therapeutics Limited | Modified natural killer cells and natural killer cell lines having increased cytotoxicity |
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| JP7373991B2 (ja) * | 2016-07-15 | 2023-11-06 | ビラクタ セラピューティクス，インク． | 免疫療法で使用するためのヒストン脱アセチル化酵素阻害剤 |
| US10799536B2 (en) | 2016-12-09 | 2020-10-13 | Onk Therapeutics Limited | Method of treating multiple myeloma using natural killer cells expressing a chimeric antigen receptor for CD38 |
| AU2019271366B2 (en) * | 2018-05-16 | 2026-02-26 | Research Institute At Nationwide Children's Hospital | Generation of knock-out primary and expanded human NK cells using Cas9 ribonucleoproteins |
| JP7241161B2 (ja) * | 2018-08-01 | 2023-03-16 | イミュニティーバイオ、インコーポレイテッド | 細胞免疫療法の安定した遺伝子改変のための、ホーミング受容体又はサイトカインとキメラ抗原受容体とを含むクアドリシストロニックシステム |
| EP3843750A4 (en) * | 2018-08-29 | 2022-05-25 | Academia Sinica | COMBINATION OF NATURAL KILLER CELLS AND CYCLOPHOSPHAMIDE COMPOUNDS FOR THE TREATMENT OF CANCER |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| WO2020189942A1 (ko) * | 2019-03-15 | 2020-09-24 | 한국과학기술연구원 | 암 상살 능력이 향상된 면역세포 |
| KR102292657B1 (ko) | 2019-03-15 | 2021-08-24 | 한국과학기술연구원 | 암 상살 능력이 향상된 면역세포 |
| CN109970869A (zh) * | 2019-04-12 | 2019-07-05 | 南京卡提医学科技有限公司 | 一种靶向人trail死亡受体的嵌合受体配体及其应用 |
| US20220193138A1 (en) * | 2019-04-25 | 2022-06-23 | Purdue Research Foundation | Engineered natural killer cells redirected toward purinergic signaling, constructs thereof, and methods for using the same |
| KR20220093337A (ko) * | 2019-10-31 | 2022-07-05 | 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 | Cd38 녹아웃 일차 및 확장된 인간 nk 세포의 생성 |
| WO2021146521A1 (en) * | 2020-01-16 | 2021-07-22 | Acepodia Biotechnologies Ltd. | A novel cd16+ natural killer cell and a method of culturing cd16+ natural killer cell |
| US11230699B2 (en) | 2020-01-28 | 2022-01-25 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors |
| WO2021209625A1 (en) * | 2020-04-17 | 2021-10-21 | Onk Therapeutics Limited | High potency natural killer cells |
| EP4205761A4 (en) * | 2020-08-27 | 2024-05-29 | Cellid Co., Ltd | NOVEL RECOMBINANT CORONAVIRUS SPIKE PROTEIN, POLYNUCLEOTIDE ENCODING THE SAME, VECTOR COMPRISING THE POLYNUCLEOTIDE, AND VACCINE FOR THE PREVENTION OR TREATMENT OF CORONAVIRUS INFECTION, COMPRISING THE VECTOR |
| EP4204546A1 (en) | 2020-08-31 | 2023-07-05 | City of Hope | Novel cell lines, methods of producing natural killer cells and uses thereof |
| CN114426583B (zh) * | 2020-10-29 | 2023-10-10 | 中国科学技术大学 | 用于急性髓系白血病的细胞疗法的嵌合抗原受体 |
| KR20220091426A (ko) * | 2020-12-23 | 2022-06-30 | 주식회사 휴먼셀바이오 | 혈액 유래 물질 및 면역세포를 포함하는 암 또는 면역질환의 예방 또는 치료용 약학조성물 |
| JP2024522756A (ja) | 2021-06-18 | 2024-06-21 | オーエヌケイ セラピューティクス リミテッド | ダブルノックアウトナチュラルキラー細胞 |
| US20240316102A1 (en) | 2021-07-01 | 2024-09-26 | Indapta Therapeutics, Inc. | Engineered natural killer (nk) cells and related methods |
| WO2023010038A1 (en) * | 2021-07-29 | 2023-02-02 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Synthetic nucleic acid elements for enhancing car t cell efficacy |
| US20250145693A1 (en) * | 2021-09-18 | 2025-05-08 | Sunnybay Biotech, Inc. | Herv-k antibody, cell, vaccine, and drug therapeutics |
| WO2023102201A2 (en) * | 2021-12-03 | 2023-06-08 | University Of Utah Research Foundation | High selective cd229 antigen binding domains and methods of use |
| CA3259982A1 (en) | 2022-06-30 | 2024-01-04 | Indapta Therapeutics, Inc. | COMBINATION OF MODIFIED NATURAL KILLER (NK) CELLS AND ANTIBODY THERAPY AND ASSOCIATED METHODS |
| EP4353741A1 (en) | 2022-10-14 | 2024-04-17 | ONK Therapeutics Limited | Double knockout natural killer cells |
| EP4615471A1 (en) | 2022-11-10 | 2025-09-17 | ONK Therapeutics Limited | Combined therapies using immunomodulating drugs |
| WO2024238387A1 (en) * | 2023-05-12 | 2024-11-21 | Nkmax Co., Ltd. | Method of treating alzheimer's disease with expanded natural killer cells |
| WO2025059162A1 (en) | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Car-engager containing il-2 variants to enhance the functionality of car t cells |
| WO2025073908A1 (en) | 2023-10-05 | 2025-04-10 | Onk Therapeutics Limited | Optimised il-15 constructs |
| WO2025146467A1 (en) | 2024-01-04 | 2025-07-10 | Onk Therapeutics Limited | Targeted il-15 construct delivery |
| KR20250118299A (ko) | 2024-01-29 | 2025-08-06 | 인하대학교 산학협력단 | 전기자극 시스템을 활용한 자연살해세포의 암세포 살상 능력 증진 방법 |
| WO2025184169A1 (en) * | 2024-02-26 | 2025-09-04 | The Regents Of The University Of California | Oleate-mediated enhancement of human natural killer cell function |
| WO2025239292A1 (ja) * | 2024-05-15 | 2025-11-20 | 株式会社Cured | 改変ナチュラルキラー細胞株 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2516128A1 (en) * | 2003-02-14 | 2004-09-02 | Sagres Discovery, Inc. | Therapeutic targets in cancer |
| EP3312196B1 (en) | 2005-03-23 | 2019-07-17 | Genmab A/S | Antibodies against cd38 for treatment of multiple myeloma |
| NZ576122A (en) | 2006-09-26 | 2012-09-28 | Genmab As | Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors |
| JP2010507366A (ja) | 2006-10-19 | 2010-03-11 | メルク アンド カンパニー インコーポレイテッド | インターロイキン−１３受容体α１の抗体アンタゴニスト |
| GB0724532D0 (en) | 2007-12-17 | 2008-01-30 | Nat Univ Ireland | Trail variants for treating cancer |
| EP3613774A1 (en) * | 2010-06-09 | 2020-02-26 | Genmab A/S | Antibodies against human cd38 |
| EP2964753B1 (en) | 2013-03-07 | 2018-04-25 | Baylor College of Medicine | Targeting cd138 in cancer |
| US10836998B2 (en) * | 2014-02-14 | 2020-11-17 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
| JP6772063B2 (ja) * | 2014-02-14 | 2020-10-21 | ベリカム ファーマシューティカルズ， インコーポレイテッド | 誘導可能なキメラポリペプチドを使用して細胞を活性化するための方法 |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| JP2017513818A (ja) | 2014-03-15 | 2017-06-01 | ノバルティス アーゲー | キメラ抗原受容体を使用する癌の処置 |
| EP3237436B1 (en) | 2014-12-24 | 2019-05-01 | Aadigen, Llc | Peptides and nanoparticles for intracellular delivery of molecules |
| HK1246180A1 (zh) | 2014-12-31 | 2018-09-07 | Celgene Corporation | 使用自然杀伤细胞治疗血液病症、实体瘤或感染性疾病的方法 |
| US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| CN108603170A (zh) | 2015-06-12 | 2018-09-28 | 莱蒂恩技术公司 | 用工程改造的t细胞治疗癌症的方法 |
| JP6961497B2 (ja) | 2015-06-25 | 2021-11-05 | アイセル・ジーン・セラピューティクス・エルエルシー | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| EP3971284B1 (en) | 2015-07-29 | 2023-11-08 | ONK Therapeutics Limited | Modified natural killer cells and natural killer cell lines having increased cytotoxicity |
| US10906951B2 (en) | 2015-07-29 | 2021-02-02 | Onk Therapeutics Limited | Modified natural killer cells and natural killer cell lines having increased cytotoxicity |
| CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| WO2018104554A1 (en) | 2016-12-09 | 2018-06-14 | Onkimmune Limited | Improved nk-based cell therapy |
| US10799536B2 (en) * | 2016-12-09 | 2020-10-13 | Onk Therapeutics Limited | Method of treating multiple myeloma using natural killer cells expressing a chimeric antigen receptor for CD38 |
| US20190321402A1 (en) | 2018-04-19 | 2019-10-24 | Onkimmune Limited | Nk cells for use with anitbodies in cancer therapy |
-
2017
- 2017-12-11 US US15/837,576 patent/US10799536B2/en active Active
- 2017-12-11 ES ES17825774T patent/ES2746856T3/es active Active
- 2017-12-11 JP JP2019551736A patent/JP7228900B2/ja active Active
- 2017-12-11 BR BR112019011450-5A patent/BR112019011450A2/pt not_active IP Right Cessation
- 2017-12-11 MX MX2019006598A patent/MX2019006598A/es unknown
- 2017-12-11 EP EP21160170.3A patent/EP3895712B1/en active Active
- 2017-12-11 CA CA3045386A patent/CA3045386A1/en active Pending
- 2017-12-11 EP EP19176141.0A patent/EP3581190B1/en active Active
- 2017-12-11 EP EP22179362.3A patent/EP4104841A1/en active Pending
- 2017-12-11 ES ES21160170T patent/ES2926397T3/es active Active
- 2017-12-11 CN CN202311063691.5A patent/CN117305250A/zh active Pending
- 2017-12-11 DK DK17825774.7T patent/DK3454871T3/da active
- 2017-12-11 DK DK19176141.0T patent/DK3581190T3/da active
- 2017-12-11 KR KR1020197019363A patent/KR20190114966A/ko not_active Ceased
- 2017-12-11 EP EP17825774.7A patent/EP3454871B1/en active Active
- 2017-12-11 WO PCT/EP2017/082292 patent/WO2018104562A1/en not_active Ceased
- 2017-12-11 AU AU2017371517A patent/AU2017371517B2/en active Active
- 2017-12-11 CN CN201780085686.0A patent/CN110248669B/zh active Active
- 2017-12-11 ES ES19176141T patent/ES2875005T3/es active Active
-
2020
- 2020-08-31 US US17/008,506 patent/US12534536B2/en active Active
-
2023
- 2023-02-07 JP JP2023017202A patent/JP2023052980A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020503891A5 (enExample) | ||
| HRP20161656T4 (hr) | Sredstva za vezanje na cd33 | |
| ZA202206437B (en) | Claudin18.2 binding moieties and uses thereof | |
| JP2016520074A5 (enExample) | ||
| PH12018501778A1 (en) | Antibodies to tigit | |
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| PH12019502356A1 (en) | Trem2 antigen binding proteins and uses thereof | |
| HRP20240719T1 (hr) | Kimerna i humanizirana monoklonska protutijela protiv ljudskog ctla4 i njihova upotreba | |
| JP2012254092A5 (enExample) | ||
| JP2014505463A5 (enExample) | ||
| JP2020526214A5 (enExample) | ||
| CL2018003608A1 (es) | Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente interleucina-25 hjumana (il-2525); composición farmacéutica que lo comprende; uso de dicha composición farmacéutica para tratar una enfermedad o trastorno asociado con la actividad o expresión de il-25. (divisional solicitud 201700703) | |
| JP2017518258A5 (enExample) | ||
| JP2016502515A5 (enExample) | ||
| MX2022003249A (es) | Anticuerpos anti receptor del factor de necrosis tumoral 2 (tnfr2) y métodos de uso. | |
| JP2015535691A5 (enExample) | ||
| NZ628528A (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| WO2016014565A3 (en) | Treatment of cancer using humanized anti-bcma chimeric antigen receptor | |
| JP2017513478A5 (enExample) | ||
| JP2014039548A5 (enExample) | ||
| JP2015131795A5 (enExample) | ||
| WO2015142675A3 (en) | Treatment of cancer using chimeric antigen receptor | |
| JP2018524326A5 (enExample) | ||
| JP2017537972A5 (enExample) | ||
| JP2018509163A5 (enExample) |